Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Leiomyosarcoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Leiomyosarcoma - Pipeline Review, H2 2015', provides an overview of the Leiomyosarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Leiomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leiomyosarcoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Leiomyosarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Leiomyosarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Leiomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Leiomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Leiomyosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Leiomyosarcoma Overview 7 Therapeutics Development 8 Pipeline Products for Leiomyosarcoma - Overview 8 Pipeline Products for Leiomyosarcoma - Comparative Analysis 9 Leiomyosarcoma - Therapeutics under Development by Companies 10 Leiomyosarcoma - Therapeutics under Investigation by Universities/Institutes 11 Leiomyosarcoma - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Leiomyosarcoma - Products under Development by Companies 15 Leiomyosarcoma - Products under Investigation by Universities/Institutes 16 Leiomyosarcoma - Companies Involved in Therapeutics Development 17 Karyopharm Therapeutics, Inc. 17 Merck & Co., Inc. 18 Mirati Therapeutics Inc. 19 Novartis AG 20 Pharma Mar, S.A. 21 Vicore Pharma AB 22 Leiomyosarcoma - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 C-21 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 everolimus - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 mocetinostat - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 NOV-110501 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 pazopanib hydrochloride - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 pembrolizumab - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 selinexor - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 trabectedin - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Leiomyosarcoma - Recent Pipeline Updates 69 Leiomyosarcoma - Dormant Projects 101 Leiomyosarcoma - Discontinued Products 102 Leiomyosarcoma - Product Development Milestones 103 Featured News & Press Releases 103 Jun 01, 2015: Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 103 May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma 104 May 13, 2015: Janssen to Showcase Data from Compound Trabectedin at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting 105 Feb 17, 2014: Yondelis recommended by the National Comprehensive Cancer Network to treat uterine leiomyosarcoma in clinical trials 106 Appendix 107 Methodology 107 Coverage 107 Secondary Research 107 Primary Research 107 Expert Panel Validation 107 Contact Us 107 Disclaimer 108
List of Tables
Number of Products under Development for Leiomyosarcoma, H2 2015 8 Number of Products under Development for Leiomyosarcoma - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Late Stage Development, H2 2015 12 Comparative Analysis by Clinical Stage Development, H2 2015 13 Comparative Analysis by Early Stage Development, H2 2015 14 Products under Development by Companies, H2 2015 15 Products under Investigation by Universities/Institutes, H2 2015 16 Leiomyosarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 17 Leiomyosarcoma - Pipeline by Merck & Co., Inc., H2 2015 18 Leiomyosarcoma - Pipeline by Mirati Therapeutics Inc., H2 2015 19 Leiomyosarcoma - Pipeline by Novartis AG, H2 2015 20 Leiomyosarcoma - Pipeline by Pharma Mar, S.A., H2 2015 21 Leiomyosarcoma - Pipeline by Vicore Pharma AB, H2 2015 22 Assessment by Monotherapy Products, H2 2015 23 Number of Products by Stage and Target, H2 2015 25 Number of Products by Stage and Mechanism of Action, H2 2015 27 Number of Products by Stage and Route of Administration, H2 2015 29 Number of Products by Stage and Molecule Type, H2 2015 31 Leiomyosarcoma Therapeutics - Recent Pipeline Updates, H2 2015 69 Leiomyosarcoma - Dormant Projects, H2 2015 101 Leiomyosarcoma - Discontinued Products, H2 2015 102
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
